共 69 条
- [2] Baglia ML, 2018, CANCER EPIDEM BIOMAR, V27, P315, DOI [10.1158/1055-9965.EPI-17-0837, 10.1158/1055-9965.epi-17-0837]
- [9] Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 3246 - +